Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial in a breakthrough for regenerative medicine

Home/News/News/Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial in a breakthrough for regenerative medicine

Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial in a breakthrough for regenerative medicine

Asterias Biotherapeutics (NYSE: AST) recently announced ground-breaking results restoring function to patients with spinal injuries from a Phase 1 clinical trial that were nothing short of astounding. 

AST’s technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime’s CEO, Dr. Michael West, is one of the world’s leading experts in regenerative and stem cell research

 


Original source of this content: http://www.nextbigfuture.com/2016/12/oligodendrocyte-progenitor-cells-repair.html